{
    "info": {
        "nct_id": "NCT04616196",
        "official_title": "A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors",
        "inclusion_criteria": "* Histologically confirmed diagnosis of a locally advanced or metastatic HNSCC, CRC, cSCC, ASCC, or cervical cancer.\n* Life expectancy > 12 weeks as determined by the Investigator.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Measurable disease per RECIST 1.1.\n\nHNSCC:\n\n* Progression on any first or second line platinum-based chemotherapy and/or anti-PD-1 or programmed death-ligand 1 antibody.\n\nCRC:\n\n* Patients must have received or were intolerant to at least 2 prior cancer therapy regimens administered for metastatic disease.\n\ncSCC\n\n* Patients must have received prior therapy including anti-PD-1 and platinum-based chemotherapy, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.\n\naSCC\n\n* Patients must have received prior therapy including anti-PD-1 and platinum-based chemotherapy, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.\n* If human immunodeficiency virus (HIV)-positive, patients must also have CD4+ count ≥ 300/μL, undetectable viral load, and be receiving highly active antiretroviral therapy at the time of screening.\n\nCervical Cancer\n\n* Patients must have experienced progression (or toxicity precluding additional treatment) on any first- or second-line platinum-based chemotherapy and anti-PD-(L)1, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.\n* Patients must have known status by pathology for HPV\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s)\n* Prior surgery or radiotherapy within 14 days of initiating study drug(s)\n* Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis; active infection requiring systemic therapy within 7 days prior to dosing\n* Patients who have been previously treated with IL-2 or IL-15\n* Known Grade 3 or 4 hypersensitivity reaction to cetuximab, history of allergy to red meat or tick bites, or history of positive test results for immunoglobulin E antibodies against cetuximab\n* Patients who have an active, known, or suspected autoimmune disease\n\nNOTE: Other protocol defined inclusion/exclusion criteria may apply",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If human immunodeficiency virus (HIV)-positive, patients must also have CD4+ count ≥ 300/μL, undetectable viral load, and be receiving highly active antiretroviral therapy at the time of screening.",
            "criterions": [
                {
                    "exact_snippets": "If human immunodeficiency virus (HIV)-positive",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CD4+ count ≥ 300/μL",
                    "criterion": "CD4+ count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 300,
                                "unit": "μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    ]
                },
                {
                    "exact_snippets": "be receiving highly active antiretroviral therapy at the time of screening",
                    "criterion": "highly active antiretroviral therapy (HAART)",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "aSCC",
            "criterions": [
                {
                    "exact_snippets": "aSCC",
                    "criterion": "aSCC",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have experienced progression (or toxicity precluding additional treatment) on any first- or second-line platinum-based chemotherapy and anti-PD-(L)1, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.",
            "criterions": [
                {
                    "exact_snippets": "Patients must have experienced progression (or toxicity precluding additional treatment) on any first- or second-line platinum-based chemotherapy and anti-PD-(L)1",
                    "criterion": "prior treatment with platinum-based chemotherapy and anti-PD-(L)1",
                    "requirements": [
                        {
                            "requirement_type": "treatment_line",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "line"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "line"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "platinum-based chemotherapy",
                                "anti-PD-(L)1"
                            ]
                        },
                        {
                            "requirement_type": "treatment_outcome",
                            "expected_value": [
                                "progression",
                                "toxicity precluding additional treatment"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have documented platinum-refractory disease",
                    "criterion": "platinum-refractory disease",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be ineligible/unfit for platinum-based therapy",
                    "criterion": "eligibility for platinum-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "fitness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy > 12 weeks as determined by the Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy > 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "HNSCC:",
            "criterions": [
                {
                    "exact_snippets": "HNSCC:",
                    "criterion": "HNSCC (head and neck squamous cell carcinoma)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "CRC:",
            "criterions": [
                {
                    "exact_snippets": "CRC",
                    "criterion": "colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have received prior therapy including anti-PD-1 and platinum-based chemotherapy, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.",
            "criterions": [
                {
                    "exact_snippets": "received prior therapy including anti-PD-1 and platinum-based chemotherapy",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "anti-PD-1 therapy received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "platinum-based chemotherapy received",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented platinum-refractory disease",
                    "criterion": "platinum-refractory disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ineligible/unfit for platinum-based therapy",
                    "criterion": "eligibility for platinum-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "ineligibility or unfitness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "cSCC",
            "criterions": [
                {
                    "exact_snippets": "cSCC",
                    "criterion": "cutaneous squamous cell carcinoma (cSCC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have known status by pathology for HPV",
            "criterions": [
                {
                    "exact_snippets": "Patients must have known status by pathology for HPV",
                    "criterion": "HPV status by pathology",
                    "requirements": [
                        {
                            "requirement_type": "known status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Cervical Cancer",
            "criterions": [
                {
                    "exact_snippets": "Cervical Cancer",
                    "criterion": "cervical cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed diagnosis of a locally advanced or metastatic HNSCC, CRC, cSCC, ASCC, or cervical cancer.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed diagnosis",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "histological"
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic HNSCC, CRC, cSCC, ASCC, or cervical cancer",
                    "criterion": "cancer type and stage",
                    "requirements": [
                        {
                            "requirement_type": "cancer type",
                            "expected_value": [
                                "HNSCC",
                                "CRC",
                                "cSCC",
                                "ASCC",
                                "cervical cancer"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have received or were intolerant to at least 2 prior cancer therapy regimens administered for metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "Patients must have received ... at least 2 prior cancer therapy regimens administered for metastatic disease.",
                    "criterion": "prior cancer therapy regimens for metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "number received or intolerant to",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST 1.1.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have received prior therapy including anti-PD-1 and platinum-based chemotherapy, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.",
            "criterions": [
                {
                    "exact_snippets": "Patients must have received prior therapy including anti-PD-1",
                    "criterion": "prior anti-PD-1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must have received prior therapy including ... platinum-based chemotherapy",
                    "criterion": "prior platinum-based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have documented platinum-refractory disease",
                    "criterion": "platinum-refractory disease",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": "platinum-refractory"
                        }
                    ]
                },
                {
                    "exact_snippets": "be ineligible/unfit for platinum-based therapy",
                    "criterion": "eligibility for platinum-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "fitness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progression on any first or second line platinum-based chemotherapy and/or anti-PD-1 or programmed death-ligand 1 antibody.",
            "criterions": [
                {
                    "exact_snippets": "Progression on any first or second line platinum-based chemotherapy",
                    "criterion": "progression on platinum-based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "line of therapy",
                            "expected_value": [
                                "first",
                                "second"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Progression on ... anti-PD-1 or programmed death-ligand 1 antibody",
                    "criterion": "progression on anti-PD-1 or PD-L1 antibody",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients who have an active, known, or suspected autoimmune disease",
            "criterions": [
                {
                    "exact_snippets": "active, known, or suspected autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "NOTE: Other protocol defined inclusion/exclusion criteria may apply",
            "criterions": [
                {
                    "exact_snippets": "Other protocol defined inclusion/exclusion criteria may apply",
                    "criterion": "other protocol defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior surgery or radiotherapy within 14 days of initiating study drug(s)",
            "criterions": [
                {
                    "exact_snippets": "Prior surgery ... within 14 days of initiating study drug(s)",
                    "criterion": "prior surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior ... radiotherapy within 14 days of initiating study drug(s)",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis; active infection requiring systemic therapy within 7 days prior to dosing",
            "criterions": [
                {
                    "exact_snippets": "Evidence of clinically significant interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "active, noninfectious pneumonitis",
                    "criterion": "noninfectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection requiring systemic therapy within 7 days prior to dosing",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic therapy"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to dosing"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have been previously treated with IL-2 or IL-15",
            "criterions": [
                {
                    "exact_snippets": "Patients who have been previously treated with IL-2",
                    "criterion": "prior IL-2 treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have been previously treated with ... IL-15",
                    "criterion": "prior IL-15 treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s)",
            "criterions": [
                {
                    "exact_snippets": "Use of an investigational agent ... within 28 days before administration of first dose of study drug(s)",
                    "criterion": "use of investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of ... an investigational device within 28 days before administration of first dose of study drug(s)",
                    "criterion": "use of investigational device",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known Grade 3 or 4 hypersensitivity reaction to cetuximab, history of allergy to red meat or tick bites, or history of positive test results for immunoglobulin E antibodies against cetuximab",
            "criterions": [
                {
                    "exact_snippets": "Known Grade 3 or 4 hypersensitivity reaction to cetuximab",
                    "criterion": "hypersensitivity reaction to cetuximab",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Grade 3",
                                "Grade 4"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of allergy to red meat",
                    "criterion": "allergy to red meat",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of allergy to ... tick bites",
                    "criterion": "allergy to tick bites",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of positive test results for immunoglobulin E antibodies against cetuximab",
                    "criterion": "immunoglobulin E antibodies against cetuximab",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}